Invivyd's REVOLUTION program for VYD2311 advances, but analysts see no shift in long-term revenue growth outlook.

Invivyd's latest clinical progress has left its fair value estimate at $10.00 per share, with a slight uptick in the discount rate indicating a modest shift in perceived risk. Analysts interpret the stable long-term revenue growth outlook as reinforcement of expectations for VYD2311's potential to reshape Invivyd's market opportunity. H.C. Wainwright doubled its price target to $10, signaling improved confidence in Invivyd's execution and long-term growth prospects in COVID-19 prevention.